bl-b01d1
biokin pharma
['lcsm,(-blcsm)', 'bl-b01d1', 'nsclc', 'sclc']
early results from the fih phase 1 study of bl-b01d1, a first-in-class egfrxher3 bispecific adc: hematological aes most prevalent, no dlts, no ild orr = 45.3% across different tumor types orr = 63.2% in egfrm nsclc with a majority after 3rd generation tkis #asco23 #lcsm 
Med Onc, Clinical Trials Development Leader @JulesBordet #BreastCancer #PrecisionMedicine. Views are mine https://t.co/F0nn6X9z9N…